Mithra Through a Tough Period
Ahead of Mithra's upcoming FY22 results, we reviewed our financial forecasts and took a closer look at Mithra's flexible equity lines. Despite the company developing contraceptive drugs to stop bleeding, shareholders have gone through a particularly tough period over the past 18 months. Our valuation suggests a market overreaction over the past twelve months, however Mithra's use of flexible equity lines that are linked to the company's share price could trigger increasing levels of dilution. As a result, we revise our TP from € 11 to € 5.3 and move to an Accumulate rating.Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.